The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Current overview of statin-induced myopathy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2998 · Cited by 1,331
Current Perspectives on Statins
Maron, D. J., Fazio, S., & Linton, M. F. (2000) · Circulation · doi:10.1161/01.cir.101.2.207 · Cited by 1,213
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Rosenson, R. S., & Tangney, C. C. (1998) · JAMA · doi:10.1001/jama.279.20.1643 · Cited by 954
Self-citationDrug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 845
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
(1998) · Circulation · doi:10.1161/01.cir.97.15.1440 · Cited by 796
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626
Pedersen, T. R., Olsson, A. G., Færgeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyörälä, K., et al. (1998) · Circulation · doi:10.1161/01.cir.97.15.1453 · Cited by 621
Statin-associated myopathy with normal creatine kinase levels
Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., England, J. D. F., & and the Scripps Mercy Clinical Research Center* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00009 · Cited by 565
Sever, P. S., Dahl??f, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2004) · Drugs · doi:10.2165/00003495-200464002-00005 · Cited by 524
Hamelin, B. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01147-4 · Cited by 468
McTaggart, F., Buckett, L., Davidson, R., Holdgate, G., McCormick, A., Schneck, D., Smith, G., & Warwick, M. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01454-0 · Cited by 413
Neuvonen, P. J., Kantola, T., & Kivistö, K. T. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90165-5 · Cited by 406
Withdrawal of Cerivastatin from the World Market
Furberg, C. D., & Pitt, B. (2001) · Trials · doi:10.1186/cvm-2-5-205 · Cited by 400
Sacks, F. M., Moyé, L. A., Davis, B. R., Cole, T. G., Rouleau, J. L., Nash, D. T., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.97.15.1446 · Cited by 376
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
Prueksaritanont, T., Subramanian, R., Fang, X., Ma, B., Qiu, Y., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.505 · Cited by 344
Gemfibrozil greatly increases plasma concentrations of cerivastatin
Backman, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 336
Efficacy and long-term adverse effect pattern of lovastatin
Tobert, J. A. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90004-5 · Cited by 335
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
Prueksaritanont, T., Tang, C., Qiu, Y., Mu, L., Subramanian, R., & Lin, J. H. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1280 · Cited by 325
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Effect of itraconazole on the pharmacokinetics of atorvastatin*
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90023-6 · Cited by 300
HMG-CoA Reductase Inhibitors and Myotoxicity
Ucar, M., Mjorndal, T., & Dahlqvist, R. (2000) · Drug Safety · doi:10.2165/00002018-200022060-00003 · Cited by 279
Shepherd, J., Blauw, G. J., & Murphy, M. B. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00040-0 · Cited by 273
Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)
Miller, D. B., & Spence, J. D. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199834020-00003 · Cited by 259
Simes, R. J., Marschner, I. C., Hunt, D., Colquhoun, D., Sullivan, D., Stewart, R. A. H., Hague, W., Keech, A., Thompson, P., White, H., et al. (2002) · Circulation · doi:10.1161/hc1002.105136 · Cited by 254
Pfeffer, M. A., Keech, A., Sacks, F. M., Cobbe, S. M., Tonkin, A., Byington, R. P., Davis, B. R., Friedman, C. P., & Braunwald, E. (2002) · Circulation · doi:10.1161/01.cir.0000017634.00171.24 · Cited by 241
Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
Neuvonen, P. J., & Jalava, K.-M. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90167-8 · Cited by 238
Christians, U., Jacobsen, W., & Floren, L. C. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00016-3 · Cited by 220
Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle: Are all Statins the Same?
Evans, M., & Rees, A. (2002) · Drug Safety · doi:10.2165/00002018-200225090-00004 · Cited by 210
Lipid-Lowering Drugs and Risk of Myopathy: A Population-Based Follow-Up Study
Gaist, D., Alberto García Rodríguez, L., Huerta, C., Hallas, J., & Sindrup, S. H. (2001) · Epidemiology · doi:10.1097/00001648-200109000-00017 · Cited by 210
Rosuvastatin: A Highly Effective New HMG‐CoA Reductase Inhibitor
Olsson, A. G., McTaggart, F., & Raza, A. (2002) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2002.tb00099.x · Cited by 204
Kyrklund, C., Backman, J. T., Kivistö, K. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115542 · Cited by 191
Brown, A. S., Bakker-Arkema, R. G., Yellen, L., Henley, R. W., Guthrie, R., Campbell, C. F., Koren, M., Woo, W., McLain, R., & Black, D. M. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00300-3 · Cited by 182
Andrews, T. C., Ballantyne, C. M., Hsia, J. A., & Kramer, J. H. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00799-9 · Cited by 177
Laaksonen, R., Jokelainen, K., Laakso, J., Sahi, T., Härkönen, M., Tikkanen, M. J., & Himberg, J.-J. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89180-1 · Cited by 171
Ellen, R. L. B., & McPherson, R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00040-x · Cited by 169
Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia
Wiklund, O., Angelin, B., Bergman, M., Berglund, L., Bondjers, G., Carlsson, A., Linden, T., Miettinen, T., Ödman, B., Olofsson, S.-O., et al. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90114-5 · Cited by 165
Athyros, V. G., Papageorgiou, A. A., Hatzikonstandinou, H. A., Didangelos, T., Carina, M., Kranitsas, D. F., & Kontopoulos, A. G. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00430-x · Cited by 157
Lovastatin, Nicotinic Acid, and Rhabdomyolysis
Reaven, P. D., & Witztum, J. L. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-7-597_2 · Cited by 152
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen, X., Wang, J. S., Backman, J. T., Kivistö, K. T., & Neuvonen, P. J. (2001) · PubMed · Cited by 139
Masters, B. A., Palmoski, M. J., Flint, O. P., Gregg, R. E., Wang‐Iverson, D. B., & Durham, S. K. (1995) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1995.1058 · Cited by 132
Quintrec, J. S. L., & Quintrec, J.-S. G.-L. (1991) · Baillière s Clinical Rheumatology · doi:10.1016/s0950-3579(05)80294-8 · Cited by 130
Rhabdomyolysis After Taking Atorvastatin With Gemfibrozil
Duell, P. B., Connor, W. E., & Illingworth, D. R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00907-7 · Cited by 118
Nakahara, K., Kuriyama, M., Sonoda, Y., Yoshidome, H., Nakagawa, H., Fujiyama, J., Higuchi, I., & Osame, M. (1998) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1998.8491 · Cited by 116
Screening for Statin-Related Toxicity
Smith, C. C., Bernstein, L. I., Davis, R. B., Rind, D. M., & Shmerling, R. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.6.688 · Cited by 110
Hamilton‐Craig, I. R. (2001) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2001.tb143683.x · Cited by 109
Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.
Watts, G. F., Castelluccio, C., Rice-Evans, C. A., Taub, N. A., Baum, H., & Quinn, P. J. (1993) · Journal of Clinical Pathology · doi:10.1136/jcp.46.11.1055 · Cited by 109
Learning from the cerivastatin experience
Farmer, J. A. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06489-3 · Cited by 105
Martin, P. D., Dane, A. L., Schneck, D. W., & Warwick, M. J. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80089-9 · Cited by 103
Adverse Effects of Drugs on Muscle
Mastaglia, F. L. (1982) · Drugs · doi:10.2165/00003495-198224040-00003 · Cited by 99
Madariaga, M. G., Gamarra, N., Dempsey, S., & Barsano, C. P. (2002) · Thyroid · doi:10.1089/10507250252949478 · Cited by 99
Pan, W., Gustavson, L. E., Achari, R., Rieser, M. J., Ye, X., Gutterman, C., & Wallin, B. A. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022008874 · Cited by 91
Davignon, J., Roederer, G., Montigny, M., Hayden, M. R., Tan, M.-H., Connelly, P., Hegele, R., McPherson, R., Lupien, P., Gagné, C., et al. (1994) · American Journal of Cardiology · doi:10.1016/0002-9149(94)90005-1 · Cited by 90
Discontinuation rates of cholesterol-lowering medications: implications for primary care.
Hiatt, J. G., Sg, S., & Schectman, G. (1999) · The American Journal of Managed Care · Cited by 85
Rhode Island physicians' recognition and reporting of adverse drug reactions.
Scott, H. D., Rosenbaum, S. E., Wj, W., Colt, A. M., Lg, A., Juergens, J. P., & Ga, F. (1987) · PubMed · Cited by 77
The effect of pravastatin and atorvastatin on coenzyme Q10
Bleske, B. E., Willis, R. A., Anthony, M. J., Casselberry, N., Datwani, M., Uhley, V. E., Secontine, S. G., & Shea, M. J. (2001) · American Heart Journal · doi:10.1067/mhj.2001.116762 · Cited by 77
Hunninghake, D. B., Bakker-Arkema, R. G., Wigand, J., Drehobl, M., Schrott, H. G., Early, J. L., Abdallah, P., McBride, S. J., & Black, D. M. (1998) · PubMed · Cited by 71
Bargossi, A., Battino, M. A., Gaddi, A. V., Fiorella, P. L., Grossi, G., Barozzi, G., Giulio, R. D., Descovich, G. C., Sassi, S., Genova, M. L., et al. (1994) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02592449 · Cited by 70
Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin
Gadbut, A. P., Caruso, A. P., & Galper, J. (1995) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(95)92163-x · Cited by 68
Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil
van Puijenbroek, E., du Buf-Vereijken, P. W. G., Spooren, P. F. M. J., et al. (1996) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1996.48879000.x · Cited by 67
Bliznakov, E. G. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)00150-0 · Cited by 66
Can Statins Cause Chronic Low-Grade Myopathy?
Grundy, S. M. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00015 · Cited by 64
Rhabdomyolysis and Satin Therapy: Relevance to the Elderly
Sica, D. A., & Gehr, T. W. B. (2002) · The American Journal of Geriatric Cardiology · doi:10.1111/j.1076-7460.2002.01422.x · Cited by 62
Reijneveld, J. C., Koot, R. W., Bredman, J. J., Joles, J. A., & Bär, P. R. (1996) · Pediatric Research · doi:10.1203/00006450-199606000-00016 · Cited by 57
Bone and joint manifestations of hypothyroidism
McLean, R. M., & Podell, D. N. (1995) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(95)80038-7 · Cited by 57
Does differing metabolism by cytochrome P450 have clinical importance?
Davidson, M. H. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0090-4 · Cited by 54
Enhancement of Membrane Fluidity in Cholesterol-Poor Endothelial Cells Pre-treated with Simvastatin
Morita, I., Sato, I., Ma, L., & Murota, S. (1997) · Endothelium · doi:10.3109/10623329709079868 · Cited by 53
Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil
Bermingham, R. P., Whitsitt, T. B., Smart, M. L., Nowak, D., & Scalley, R. D. (2000) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/57.5.461 · Cited by 52
Long‐Term safety of pravastatin‐gemfibrozil therapy in mixed hyperlipidemia
Iliadis, E. A., & Rosenson, R. S. (1999) · Clinical Cardiology · doi:10.1002/clc.4960220110 · Cited by 51
Self-citationCsako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Levy, Y., Leibowitz‐Amit, R., Aviram, M., Brook, J. G., & Cogan, U. (1992) · PubMed · Cited by 37
Sica, D. A., & Gehr, T. W. B. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200203000-00001 · Cited by 35
Effective use of statins to prevent coronary heart disease.
Crouch, M. A. (2001) · PubMed · Cited by 23
Rhabdomyolysis, Acute Renal Failure and Hepatopathy Induced by Lovastatin Monotherapy.
Chu, P., Wei-Jan, C. H. E. N., CHIANG, C.-W., & Lee, Y. (1997) · Japanese Heart Journal · doi:10.1536/ihj.38.541 · Cited by 19
Physicians’ interpretation of “class effects”
Kennedy, H. L., & Rosenson, R. S. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01913-7 · Cited by 19
Self-citationSevere Rhabdomyolysis and Cerivastatin—Gemfibrozil Combination Therapy
Roca, B., Calvo, B., & Monferrer, R. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a383 · Cited by 15
The rationale for combination therapy
Rosenson, R. S. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02966-1 · Cited by 13
Self-citation(2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00070-x · Cited by 7
Statins and the risk of rhabdomyolysis
Rosenson, R. S. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03345078 · Cited by 4
Self-citationDiscontinuation Rates of Cholesterol-Lowering Medications
Hiatt, J. G., Sg, S., & Schectman, G. (1999) · The American Journal of Managed Care · Cited by 3
Cited by
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
“6) [1-11]”
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Self-citationSLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Metadata
- Authors
- Rosenson, R. S.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 116
- Issue
- 6
- Pages
- 408-416
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W1982412102
- Cited by
- 287
- References
- 93
- FWCI
- 28.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.